You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Perjeta

Showing 1 - 25 of 134
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Healthy Men Trial in Moscow (Pertuzumab, Perjeta®)

Not yet recruiting
  • Healthy Men
  • Moscow, Russian Federation
    Central Clinical Hospital "RZD-Medicina"
Apr 11, 2023

Breast Cancer Trial in Moscow, Omsk, Saint Petersburg (BCD-178, Perjeta)

Recruiting
  • Breast Cancer
  • Moscow, Russian Federation
  • +2 more
Apr 5, 2023

Breast Cancer Trial in Saint Petersburg (BCD-178, Perjeta)

Active, not recruiting
  • Breast Cancer
  • Saint Petersburg, Russian Federation
  • +1 more
Feb 13, 2023

HER2-positive Breast Cancer Trial in Shanghai (SYSA1901, Pertuzumab, Trastuzumab)

Recruiting
  • HER2-positive Breast Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Feb 8, 2023

HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients Trial (PERT-IJS plus trastuzumab,

Not yet recruiting
  • HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
  • PERT-IJS plus trastuzumab, carboplatin and docetaxel
  • Perjeta plus trastuzumab, carboplatin and docetaxel
  • (no location specified)
Sep 21, 2023

HER2-positive Breast Cancer Trial in China (TQB2440 injection + Trastuzumab + Docetaxel, Perjeta + Trastuzumab + Docetaxel)

Active, not recruiting
  • HER2-positive Breast Cancer
  • TQB2440 injection + Trastuzumab + Docetaxel
  • Perjeta + Trastuzumab + Docetaxel
  • Chongqing, Chongqing, China
  • +5 more
Aug 3, 2023

Breast Cancer Trial in Berlin (420 mg EG1206A EirGenix Pertuzumab in 14 mL Injection, Perjeta (EU origin) 420 mg in 14 mL

Recruiting
  • Breast Cancer
  • 420 mg EG1206A EirGenix Pertuzumab in 14 mL Injection
  • +2 more
  • Berlin, Germany
    CRS Clinical Research Services Berlin GmbH
Jul 20, 2022

Similarity of Pharmacokinetics and Safety Trial (HS627(210mg/7ml), HS627(420mg/14ml), Perjeta)

Not yet recruiting
  • Similarity of Pharmacokinetics and Safety
  • (no location specified)
Apr 5, 2022

Breast Cancer, Breast Tumors, HER2-positive Breast Cancer Trial in Guanzhou (HLX11, EU-Perjeta®)

Recruiting
  • Breast Cancer
  • +2 more
  • Guanzhou, Guangdong, China
    Sun Yat-Sun Yat-sen Hospital affiliated to Sun Yat-sen Universit
Apr 28, 2022

Metastatic Breast Cancer Trial (Pertuzumab (ZRC-3277), Pertuzumab (Perjeta®))

Not yet recruiting
  • Metastatic Breast Cancer
  • Pertuzumab (ZRC-3277)
  • Pertuzumab (Perjeta®)
  • (no location specified)
Jul 11, 2022

Trastuzumab(Henlius®) Combined With Pertuzumab(Perjeta®) and

Recruiting
  • HER2-positive Metastatic Breast Cancer
  • +2 more
  • trastuzumab(Henlius®) combined with Pertuzumab(Perjeta®) and Chemotherapy
  • Beijing, Beijing, China
    Ruyan Zhang
Dec 27, 2021

Metastatic Breast Cancer Trial (BDC-1001, Pertuzumab)

Not yet recruiting
  • Metastatic Breast Cancer
  • (no location specified)
Jul 12, 2023

Breast Cancer Trial in Houston (Durvalumab, Trastuzumab, Pertuzumab)

Recruiting
  • Breast Cancer
  • Houston, Texas
    Houston Methodist Cancer Center
Aug 5, 2022

Breast Cancer Trial in Sweden (Trastuzumab deruxtecan, Docetaxel, Paclitaxel)

Not yet recruiting
  • Breast Cancer
  • Trastuzumab deruxtecan
  • +9 more
  • Malmö, Sweden
  • +6 more
Jun 8, 2023

HER2-positive Breast Cancer Trial in Tampa (biological, drug, procedure)

Recruiting
  • HER2-positive Breast Cancer
  • HER-2 pulsed DC1
  • +4 more
  • Tampa, Florida
    Moffitt Cancer Center
Oct 6, 2022

Breast Cancer Trial in Shenyang (Pyrotinib, Trastuzumab, Dalpiciclib)

Not yet recruiting
  • Breast Cancer
  • Shenyang, Liaoning, China
    Shengjing Hospital of China Medical University
Dec 2, 2022

Breast Tumors, Malignant Tumor of the Breast Trial in Multiple Locations (Trastuzumab, Pertuzumab, Vinorelbine, Paclitaxel,

Terminated
  • Breast Neoplasms
  • Malignant Tumor of the Breast
  • Multiple Locations, Texas
    19 Sites
Nov 29, 2022

Breast Cancer Trial in Helsinki (Pertuzumab, Trastuzumab)

Active, not recruiting
  • Breast Cancer
  • Helsinki, Finland
    Helsinki University Central Hospital
Mar 15, 2022

Healthy Volunteers Trial in Qingdao (recombinant mAb against human epidermal growth factor receptor injection (HS627), Perjeta

Completed
  • Healthy Volunteers
  • recombinant monoclonal antibody against human epidermal growth factor receptor injection (HS627)
  • Perjeta ®
  • Qingdao, Shandong, China
    Phase I Clinical Research Center
Mar 25, 2021

Cancer, Tumors, Tumors Trial in Denmark (Alectinib, Atezolizumab, Avelumab)

Recruiting
  • Cancer
  • +3 more
  • Aalborg, Denmark
  • +6 more
Oct 25, 2022

HER2+ Breast Cancer Trial in Xi'an (Trastuzumab, Pertuzumab, Nab paclitaxel)

Recruiting
  • HER2+ Breast Cancer
  • Xi'an, Shaanxi, China
  • +1 more
Jun 20, 2022

HER2-positive Metastatic Breast Cancer, CNS Metastases Trial in Chicago, Boston (ATEZOLIZUMAB, PERTUZUMAB, TRASTUZUMAB)

Active, not recruiting
  • HER2-positive Metastatic Breast Cancer
  • Central Nervous System Metastases
  • Chicago, Illinois
  • +1 more
Mar 14, 2022

Breast Cancer, Heart Failure Trial in Canada, Russian Federation (Trastuzumab, Pertuzumab, Trastuzumab emtansine)

Recruiting
  • Breast Cancer
  • Heart Failure
  • Hamitlon, Ontario, Canada
  • +3 more
Jun 21, 2022

Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast, Advanced Breast Cancer Trial (Trastuzumab,

Recruiting
  • Brain Metastases
  • +2 more
  • Saint Louis, Missouri
  • +1 more
Nov 8, 2022

Breast Cancer Trial in Boston, Milford, South Weymouth (Paclitaxel, Trastuzumab, Pertuzumab)

Active, not recruiting
  • Breast Cancer
  • Boston, Massachusetts
  • +4 more
Feb 4, 2022